Not a nail biter - should show huge loss but also high cash reserve and ultra high book value. Should be first appearance of new balance sheet. Overall I think a plus.
share price was reactionary along with seasonal effects. now it is acting proactively. being near yearly high in the winter indicates that either share price is ahead of itself or that this year should see impressive results.
Yes. STXS is undergoing a slow, quiet turnaround which can be accelerated. It looks like 2015 results will top 2014 results which were the bottom. Revenues went from 46.5M in 2012 to 38M in 2013 to 35M in 2014 to 37-38M+ in 2015 (guess). Look at the symmetry 2015 revenues will roughly match 2013 revenues. If company can ramp up sales to match 2012 revenues in 2016 then it should achieve GAAP breakeven or profitability. The 2012 revenues were 27M in US, 19.5M internationally. Each had roughly proportionally declined with total revenues. STXS Strong
Finance 101: Asset worth = PV of sum of future cash flows. Business performance needs to be improved so that cash flows are positive and growing. Company has superstar salespeople that need to step into senior managment role. STXS strong
my friend, you provide a wealth of useful info about the company. imo this board would be much more useful if we moved on from discussion of mills (sooo much has already been said) to a discussion of the company.
Sanderling plants seeds via startups and harvests when they are public. The stock is showing signs of strength.
Yes congress is inept but drug pricing is greedy. They need to streamline process and encourage competition.